美通社

2024-11-20 20:01

Acurx Board of Directors Approves Bitcoin as Treasury Reserve Asset

STATEN ISLAND, N.Y., Nov. 20, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company's Board of Directors approved the purchase of up to $1 million in Bitcoin to hold as a treasury reserve asset.

"As demand for Bitcoin grows, and so does its acceptance as a major and primary asset class, we believe that Bitcoin will serve as a strong treasury reserve asset for cash not needed over the next 12 to 18 months" said David P. Luci, President & CEO of Acurx. "With the recent approval of Bitcoin ETFs and the growing support from government agencies and institutional investors, it is a great addition to our treasury strategy. Its limited supply and inflation-resistant characteristics provide a functional store of value. This new treasury strategy is a finance strategy and has no impact on our overarching drug development plans."

About Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The Company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that blocks the active site of the Gram+ specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP).

To learn more about Acurx Pharmaceuticals and its product pipeline, please visit www.acurxpharma.com

Forward-Looking Statements

Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: risks inherent with investing in Bitcoin, including Bitcoin's volatility; the risks of implementing a new treasury strategy; whether ibezapolstat will benefit from the QIDP designation; whether ibezapolstat will advance through the clinical trial process on a timely basis; whether the results of the clinical trials of ibezapolstat will warrant the submission of applications for marketing approval, and if so, whether ibezapolstat will receive approval from the FDA or equivalent foreign regulatory agencies where approval is sought; whether, if ibezapolstat obtains approval, it will be successfully distributed and marketed; and other risks and uncertainties described in the Company's annual report filed with the Securities and Exchange Commission on Form 10-K for the year ended December 31, 2023, and in the Company's subsequent filings with the Securities and Exchange Commission. Such forward-looking statements speak only as of the date of this press release, and Acurx disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements, except as may be required by law.

Investor Contact:

Acurx Pharmaceuticals, Inc.
David P. Luci, President & Chief Executive Officer
Tel: 917-533-1469
Email: davidluci@acurxpharma.com

source: Acurx Pharmaceuticals, Inc.

《說說心理話》青少年自殺率上升,如何分辨求助訊號?社工分享陪伴的重要性► 即睇

人氣文章
最近7天
1
高息定存 | 6個月港元定存3.8厘新高,188日快閃優惠3.68厘
2
高息定存 | 富邦推快閃定存優惠3個月3.9厘,華僑188日3.68厘
3
港股 | 蕭猷華:內地AI發展迅速,阿里巴巴股價看俏
4
港股 | 蕭猷華:恒指料退守至18600點,宜逢低吸納
5
內銀股 | 人行再提擇機減息降準,內銀獲中金唱好,應該點部署?
6
大國博弈 | 【FOCUS】騰訊商湯寧德重挫,CMC清單劍指軍民融合
7
加州山火 | 【FOCUS】洛杉磯烈火焚城,天災背後藏人禍
8
新股掛牌 | 布魯可首日掛牌升41%,每手賺7395元
9
高息定存 | 一周高息合集,銀行高息搶存,富邦1個月4.88厘,華僑1年期3.6厘
10
高息定存 | 一周高息合集,恒生1個月定存4厘,工銀亞洲3個月最高5厘
11
英偉達 | DeepSeek衝擊AI晶片行業結構 英偉達暴跌仍未急抄底
12
高息定存 | 渣打特選客6個月3.48厘,建行亞洲推1個月6.18厘高息吸客
13
高息定存 | 花旗3個月港元定存息加至4厘,信銀國際3.88厘
14
一本萬利 | 2025年的五個「勿」(有片)
15
互聯支付 | 黃俊碩:轉數快與IBPS互聯支付所產生的發展契機
16
環球央行 | 歐洲央行宣布再次減息0.25厘,符合市場預期
17
高息定存 | 一周高息合集,銀行高息吸客,低門檻10萬享6.18厘,3個月最高5厘
18
港股 | 蕭猷華:恒指春節前目標21500點
19
財政預算案2025 | 羅兵咸料本財年財赤948億,財政儲備降至紀錄新低
20
專訪|洪灝:美股更大跌幅在前面,恐需習慣4%通脹(有片)
21
神州經脈 | 基金賣股票據報受限,滬指連跌四日,人行穩匯率
22
習近平應約與特朗普通電話,特:冀盡快與習見面
23
加州山火 | 美國洛杉磯大火失控,被迫撤離人數增至18萬
24
【FOCUS】去年貿易順差破紀錄,中國擴消費增緊迫感
25
【FOCUS】侵侵就職倒數一周,美元及油價劇本臨揭盅
26
高息定存 | 一周高息合集,部分銀行逆市加息,南商3個月加至3.8厘
27
加州山火造成超500億美元損失,大量房主未買保險
28
賣地計劃 | 政府今季推一幅東涌住宅地涉745伙,全年供應不達標
29
雷賢達觀點 | 香港篇:恒指年波幅料六千點,港須全面融入大灣區
30
新世界 | 摩通:新世界若債務違約或打開行業「潘朵拉盒子」
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

【etnet 30周年】多重慶祝活動一浪接一浪,好禮連環賞!

【蛇年行大運 新年好賞「飾」】etnet賞太歲開運趨吉避凶神器

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

大國博弈

貨幣攻略

說說心理話

聖誕新年特輯

Watch Trends 2024

北上食買玩

Art Month 2024

秋天養生食療

山今養生智慧

輕鬆護老